Green Cross Biotherapeutics Inc. (GCBT)
Established in 2014, GCBT is a Montreal-based biopharmaceutical company and a member of the Green Cross family.
Canada’s only IVIG and Albumin manufacturing Plant
GCBT will be constructing the only intravenous immunoglobulin (IVIG) and albumin manufacturing plant in Canada. This state-of-the-art facility will duly mark the beginning of a new chapter in the history of the Canadian biopharmaceutical industry.
The products that will be manufactured in this facility include intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns.
GCBT is planning to expand its business to manufacture and distribute many various bio products in the future.
Government officials and Green Cross executives pose on June 1st, 2015 at the official Ground Breaking Ceremony in St-Laurent, Quebec.
A global leader in the healthcare industry, Green Cross Corporation provides safe and effective healthcare solutions that address the evolving needs of human health. Headquartered in Yongin, South Korea, the company specializes in the development and manufacturing of plasma derivatives, preventive vaccines, recombinant proteins and therapeutic antibodies.
Green Cross Corporation was founded in 1967. With its 15 subsidiaries, it employs over 4,600 people worldwide. With more than 45 years of business experience, it has become an internationally recognized specialty bio-pharmaceutical company.